Adverse Events and Treatment Tolerability of Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: A Real World Study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background: Antifibrotic therapies slow disease progression in idiopathic pulmonary fibrosis (IPF) and are increasingly used in progressive pulmonary fibrosis (PPF), but adverse events may compromise treatment persistence. This study evaluated adverse events and treatment tolerability with pirfenidone and nintedanib in patients with IPF or PPF. Methods: This single-center ambidirectional study included 151 patients treated from January 2022 to June 2025 (120 retrospective; 31 prospective). Adverse events and treatment modifications were recorded. Results: Mean age was 67.5 ± 10.1 years; 64.9% were male, 68.9% had IPF, and 31.1% had PPF. At least one adverse event occurred in 56.3%, most commonly nausea (32.5%), vomiting (21.9%), and diarrhea (17.9%). Overall adverse-event rates were similar with pirfenidone and nintedanib (52.4% vs. 61.2%; p = 0.278). Diarrhea (6.0% vs. 32.8%; p < 0.001) and vomiting (15.5% vs. 29.9%; p = 0.034) were more frequent with nintedanib, whereas photosensitivity was more frequent with pirfenidone (16.7% vs. 1.5%; p = 0.002). Diabetes mellitus was associated with adverse events (74.1% vs. 52.4%; p = 0.040). Permanent treatment discontinuation occurred in 7.9%. Conclusions: Adverse events were common but generally manageable. The agents showed distinct adverse-event profiles, supporting early, individualized monitoring to acilitate treatment continuation.
Source: Preprints.org
Authors: Yunus Emre Er, Talat Kılıç
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225910151
